Pathologic assessment of vasculopathies in pulmonary hypertension

Giuseppe G. Pietra(National Heart Lung and Blood Institute), Rubin M. Tuder(University of Colorado Denver), Marc Humbert(Inserm), Ornella Leone(Policlinico S.Orsola-Malpighi), Susan Stewart(Papworth Hospital), Ivan M. Robbins(Vanderbilt University Medical Center), Frédérique Capron, Lynne Reid(Civil Service College)
Journal of the American College of Cardiology
June 1, 2004
10.1016/j.jacc.2004.02.033
Cited by 713

Related Papers

2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
|European Heart Journal|2022|3.6k
Survival in Patients with Primary Pulmonary Hypertension
|Annals of Internal Medicine|1991|3.5k
Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE
|Allergy|2004|1.1k
The pulmonary endothelial glycocalyx regulates neutrophil adhesion and lung injury during experimental sepsis
|Nature Medicine|2012|834
Guidelines for autopsy investigation of sudden cardiac death: 2017 update from the Association for European Cardiovascular Pathology
|Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin|2017|538